Rosen Law Firm Announces Securities Class Action Against ViroPharma Incorporated Seeking to Recover Investor Losses -- VPHM - Marketwatch

On December 14, 2011, the Company issued a press release announcing that as result of FDA approval of a supplemental new drug application, its drug Vancocin would enjoy three years of market exclusivity, and that generic Vancomycin capsules ...

Akorn Reports Record First Quarter 2012 Financial Results - Business Wire

We are excited about the growth opportunities going into the second half of this year, in particular, the recently announced FDA approval of our generic oral Vancocin®.” Consolidated revenue for the first quarter of 2012 was $51.7 million, up 103% over ...

ViroPharma Lied About Antibiotic Exclusivity, Investor Says - site.law360.com

In a suit filed in Pennsylvania federal court, the shareholder accuses the company of misleading investors with statements in December that its antibiotic brand, Vancocin, would qualify for three years of market exclusivity thanks to a new condition of use ...

5 Biotech Stocks At Rock Bottom Price With Takeover Possibility - Seekingalpha.com

On April 13, 2012, ViroPharma sued two federal agencies seeking a court order temporarily blocking approval of generic forms of its biggest product, the antibiotic Vancocin. Catalyst for Upward Movement ViroPharma's pipeline includes Cinryze (C1 esterase ...

Wounded Warriors Fight Invasive Fungal Infections - familypracticenews.com

Vancomycin (Vancocin) and meropenem (Merrem IV) also should be considered because of the high risk of coinfection with bacteria. Adjunctive therapies include minimization of immunosuppression, antimicrobial beads in open wounds, and negative-pressure wound ...

Oppenheimer Reiterates Outperform Rating, $20 PT for Optimer Pharmaceuticals - Benzinga

65% in 4Q11) from targeted hospitals is encouraging. Importantly, we continue to anticipate limited impact to DIFICID revenues from the recent introduction of generic Vancocin as a de-facto version (vancomycin slurry) was already present in the market.”

Pfenninger: Colitis associated with antibiotic use - Midland Daily News

The treatment is a different type of antibiotic. The most commonly used are metronaidzole (Flagyl) and vancomycin (Vancocin) which are taken my mouth. Newer antibiotics have also been developed. What is worrisome is that there is an emerging new ...

Oppenheimer Reiterates Outperform on Optimer Pharmaceutic (OPTR) - zolmax.com

65% in 4Q11) from targeted hospitals is encouraging. Importantly, we continue to anticipate limited impact to DIFICID revenues from the recent introduction of generic Vancocin as a de-facto version (vancomycin slurry) was already present in the market.”

VIROPHARMA INCORPORATED : Investor Alert: Former Louisiana Attorney General and .. - 4-traders (press release)

On April 10, 2012, shares of ViroPharma common stock dropped $6.17, closing at $22.44 per share, after the Company announced that the FDA would not grant additional exclusivity for its drug Vancocin. This announcement stood in stark contrast to the ...